Article
Oncology
Wing-Lok Chan, Cheuk-Wai Choi, Ian Yu-Hong Wong, Terence Hon-Ting Tsang, Adrian Tin-Chung Lam, Rosa Pui-Ying Tse, K. K. Chan, Claudia Wong, Betty Tze-Ting Law, Emina Edith Cheung, Siu-Yin Chan, Ka-On Lam, Dora Kwong, Simon Law
Summary: This study reviewed the long-term clinical outcomes and safety data of induction chemotherapy followed by surgery or definitive chemoradiotherapy in patients with locally advanced unresectable esophageal cancer. The results showed that patients who received subsequent surgery had significantly longer median overall survival compared to those who had definitive chemoradiotherapy or no definitive treatment. Induction chemotherapy followed by conversion surgery offered a chance of cure with long-term survival benefit and manageable toxicities in these patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jia-Di Wu, Zhi-Qiang Wang, Qiao-Qiao Li, Zhi-Chao Li, Chao Ren, De-Shen Wang, Ji-Yang Chen, Qiong Tan, Yu-Hong Li, Hong Yang
Summary: This study provides updated long-term follow-up data confirming the feasibility and promising survival outcomes of TPF chemotherapy followed by surgery for patients with borderline resectable esophageal squamous cell carcinoma (BR-ESCC).
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jason Chia-Hsun Hsieh, Pin-Chun Chiang, Tsung-Min Hung, Yin-Kai Chao, Yung-Chia Kuo, Chih-Tsung Wen, Po-Jung Su, Meng-Ting Peng, Huan-Wu Chen, Hui-Ling Liu, Hsien-Kun Chang, Min-Hsien Wu, Hung-Ming Wang
Summary: This study compared the effectiveness of taxane-based chemotherapy with conventional cisplatin plus 5-fluorouracil in definitive CRT for advanced esophageal squamous cell carcinoma. Results showed that the taxane-based regimen had higher response rates and longer survival times. Factors such as sex, clinical stage, radiation dose, salvage surgery, and regimen were independent prognostic factors for cancer mortality.
Article
Oncology
Ken Sasaki, Yusuke Tsuruda, Masataka Shimonosono, Masahiro Noda, Yasuto Uchikado, Takaaki Arigami, Daisuke Matsushita, Shinichiro Mori, Akihiro Nakajo, Hiroshi Kurahara, Takao Ohtsuka
Summary: This study compared the efficacy of cisplatin and 5-fluorouracil (CF) with docetaxel and CF (DCF) in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). While both groups had similar rates of pathological complete response, the DCF group showed significantly better 5-year disease-free survival and 5-year overall survival compared to the CF group.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Tetsuya Abe, Eiji Higaki, Takahiro Hosoi, Takuya Nagao, Hideaki Bando, Shigenori Kadowaki, Kei Muro, Tsutomu Tanaka, Masahiro Tajika, Yasumasa Niwa, Yasuhiro Shimizu
Summary: Induction DCF chemotherapy and subsequent conversion surgery show acceptable toxicity and offer the chance of long-term survival in patients with locally advanced unresectable esophageal cancer. The response rate to induction DCF chemotherapy was 67%, and R0 resection was achieved in 81% of patients who underwent subsequent CS.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Makoto Sakai, Makoto Sohda, Shintaro Uchida, Arisa Yamaguchi, Takayoshi Watanabe, Hideyuki Saito, Yasunari Ubukata, Nobuhiro Nakazawa, Kengo Kuriyama, Akihiko Sano, Hiroomi Ogawa, Takehiko Yokobori, Shin-Ei Noda, Tatsuya Ohno, Ken Shirabe, Hiroshi Saeki
Summary: This study evaluated the long-term outcome of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy for patients with potentially resectable esophageal cancer. The results showed a satisfactory complete response rate and overall survival rate for these patients.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Amy de Haar-Holleman, Lisa M. C. van Hoogstraten, Maarten C. C. M. Hulshof, Metin Tascilar, Katharin Bruck, Richard P. Meijer, J. Alfred Witjes, Lambertus A. Kiemeney, Katja K. H. Aben
Summary: This study compared the toxicity, overall survival (OS), and disease-free survival (DFS) between oral capecitabine and intravenous 5-fluorouracil (5-FU) in chemoradiotherapy for muscle-invasive bladder cancer (MIBC) patients. There was no significant difference in adverse events, 2-year OS, and 2-year DFS between the two regimens. Capecitabine-based CRT may be considered as an alternative to a 5-FU-based regimen.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Otorhinolaryngology
Akihiro Yamada, Hirotaka Shinomiya, Natsumi Uehara, Keisuke Iritani, Shun Tatehara, Tatsuya Furukawa, Masanori Teshima, Daisuke Miyawaki, Takeshi Fujita, Akinobu Kakigi, Naomi Kiyota, Ryohei Sasaki, Ken-ichi Nibu
Summary: This study retrospectively evaluated the efficacy, adverse events, and feasibility of TPF-CCRT in treating advanced squamous cell carcinoma of the external auditory canal (EACSCC). The results showed that TPF-CCRT had good treatment outcomes for advanced EACSCC and should be considered as a feasible treatment option.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Article
Oncology
Takahito Sugase, Keijiro Sugimura, Takashi Kanemura, Tomohira Takeoka, Masaaki Yamamoto, Naoki Shinno, Hisashi Hara, Takeshi Omori, Yoshiaki Fujii, Yosuke Mukai, Manabu Mikamori, Shinichiro Hasegawa, Naotsugu Haraguchi, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Chu Matsuda, Masayoshi Yasui, Hiroshi Miyata
Summary: This study compared postoperative recurrence patterns and outcomes in patients with radical esophagectomy after preoperative CRT or DCF. The results showed that DCF patients had fewer distant recurrences, while CRT patients had better control of locoregional recurrence but higher risk of distant recurrence.
Article
Oncology
Makoto Sakai, Makoto Sohda, Hideyuki Saito, Nobuhiro Nakazawa, Yasunari Ubukata, Kengo Kuriyama, Keigo Hara, Akihiko Sano, Hiroomi Ogawa, Takehiko Yokobori, Kazutoshi Murata, Shin-Ei Noda, Tatsuya Ohno, Ken Shirabe, Hiroshi Saeki
Summary: DCF-RT showed superior efficacy compared to CF-RT in patients with unresectable locally advanced thoracic esophageal cancer, with significantly higher rates of complete response and overall survival.
ANTICANCER RESEARCH
(2021)
Editorial Material
Medicine, General & Internal
David H. Ilson
Summary: Esophageal cancer is a major cause of cancer-related illness and death worldwide, often presenting with locally advanced or metastatic disease due to lack of effective screening or early detection. Esophageal squamous-cell carcinoma is the most common histologic type globally, especially in high-incidence areas like East Asia, while adenocarcinoma dominates in the West. Surgical outcomes for esophageal squamous-cell cancer patients in 1980 highlighted the significant challenge in treating esophageal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Osamu Shiraishi, Hiroaki Kato, Kota Momose, Yoko Hiraki, Atsushi Yasuda, Masayuki Shinkai, Motohiro Imano, Takushi Yasuda
Summary: This study investigated the impact of average relative dose intensity (RDI) of neoadjuvant chemotherapy on the prognosis of resectable locally advanced esophageal squamous cell carcinoma. The results showed that an RDI of 80% or higher improved the recurrence-free survival (RFS) in patients receiving DCF-NAC. The <80% RDI group had older individuals, lower creatinine clearance, higher comorbidity index, lower initial RDI, and lower histopathological tumor response compared to the >= 80% RDI group.
Article
Oncology
Yoichi Hamai, Manabu Emi, Yuta Ibuki, Tomoaki Kurokawa, Toru Yoshikawa, Manato Ohsawa, Ryosuke Hirohata, Yuji Murakami, Ikuno Nishibuchi, Nobuki Imano, Yasushi Nagata, Morihito Okada
Summary: This study showed that about 50% of patients diagnosed with LN metastasis before treatment were downstaged by NCRT, with relatively good prognoses. However, LN metastases were extensive in cervical, mediastinal, and abdominal areas, even within the radiation field. Therefore, systematic and adequate lymphadenectomy is required for ESCC patients treated with NCRT.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Xing Gao, Ping-Chung Tsai, Kai-Hao Chuang, Chu-Pin Pai, Po-Kuei Hsu, Shau-Hsuan Li, Hung- Lu, Joseph Jan-Baptist van Lanschot, Yin-Kai Chao
Summary: This study compared the efficacy of two commonly used neoadjuvant chemoradiotherapy regimens and found that the CROSS regimen resulted in lower treatment-related complications and better survival outcomes for Taiwanese patients with esophageal squamous cell carcinoma. These results are important for guiding treatment decisions for patients with this type of cancer in Asian populations.
Article
Cell Biology
Hung-Chang Wu, Wen-Li Ling, Chien-Liang Ling, Cheng-Yao Lin, Shang-Wen Chen, Yan-Xun Chen, Chao-Hsun Chen, Sung-Wei Lee, Shang-Hung Chen, Chao-Jung Tsao, Wen-Tsung Huang, How-Ran Guo
Summary: Adjuvant concurrent chemoradiotherapy may increase toxicities and risk of death in patients above 70 years old, but not in younger patients. It has some impact on overall survival and disease-free survival, but this impact is not significant after adjusting for other factors. Age may be a modifier of the effects of adjuvant CCRT.
